These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2289200)

  • 1. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells.
    McCune CS; O'Donnell RW; Marquis DM; Sahasrabudhe DM
    Cancer Immunol Immunother; 1990; 32(1):62-6. PubMed ID: 2289200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
    Dillman RO; Beutel LD; Cornforth AN; Nayak SK
    Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
    Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
    Wang Z; Zhang Y; Liu Y; Wang L; Zhao L; Yang T; He C; Song Y; Gao Q
    J Immunother; 2014 Jan; 37(1):43-50. PubMed ID: 24316555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of immunotherapy for metastatic renal cell carcinoma.
    Fowler JE
    J Urol; 1986 Jan; 135(1):22-5. PubMed ID: 3510318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine.
    Repmann R; Wagner S; Richter A
    Anticancer Res; 1997; 17(4B):2879-82. PubMed ID: 9329553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of adjuvant immunotherapy with autologous tumor cells and BCG in renal cancer.
    Galligioni E; Francini M; Quaia M; Carbone A; Spada A; Sacco C; Favaro D; Santarosa M; Carmignani G; Di Donna D
    Ann N Y Acad Sci; 1993 Aug; 690():367-9. PubMed ID: 8368758
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings.
    Tani K; Azuma M; Nakazaki Y; Oyaizu N; Hase H; Ohata J; Takahashi K; OiwaMonna M; Hanazawa K; Wakumoto Y; Kawai K; Noguchi M; Soda Y; Kunisaki R; Watari K; Takahashi S; Machida U; Satoh N; Tojo A; Maekawa T; Eriguchi M; Tomikawa S; Tahara H; Inoue Y; Yoshikawa H; Yamada Y; Iwamoto A; Hamada H; Yamashita N; Okumura K; Kakizoe T; Akaza H; Fujime M; Clift S; Ando D; Mulligan R; Asano S
    Mol Ther; 2004 Oct; 10(4):799-816. PubMed ID: 15451464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.
    Kugler A; Stuhler G; Walden P; Zöller G; Zobywalski A; Brossart P; Trefzer U; Ullrich S; Müller CA; Becker V; Gross AJ; Hemmerlein B; Kanz L; Müller GA; Ringert RH
    Nat Med; 2000 Mar; 6(3):332-6. PubMed ID: 10700237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
    Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.
    Faiena I; Comin-Anduix B; Berent-Maoz B; Bot A; Zomorodian N; Sachdeva A; Said J; Cheung-Lau G; Pang J; Macabali M; Chodon T; Wang X; Cabrera P; Kaplan-Lefko P; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
    J Immunother; 2020; 43(9):273-282. PubMed ID: 32925563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
    Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
    J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.
    Sahasrabudhe DM; deKernion JB; Pontes JE; Ryan DM; O'Donnell RW; Marquis DM; Mudholkar GS; McCune CS
    J Biol Response Mod; 1986 Dec; 5(6):581-94. PubMed ID: 3491881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
    Pomer S; Thiele R; Staehler G; Drehmer I; Löhrke H; Schirrmacher V
    Urologe A; 1995 May; 34(3):215-20. PubMed ID: 7610516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
    Raman R; Vaena D
    Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immune response of patients receiving specific active immunotherapy for renal cell carcinoma.
    Miller GA; Pontes JE; Huben RP; Goldrosen MH
    Cancer Res; 1985 Sep; 45(9):4478-82. PubMed ID: 4028029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.